Skip to content

Incyte

US · INCY #803 by market cap Listed 1970
114.63 -1.25 -1.07%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 5 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
101.08% +0.01pp
Institutions
1,168 -5
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund69.82%
Hedge Fund22.80%
Government Pension Fund3.33%
Public Company2.21%
Private Company1.37%
Sovereign Wealth Fund0.66%
Individual/Insider0.55%
VC/PE Fund0.21%
Family Office/Trust0.20%
Corporate Pension Plan0.18%

Top holders as of 2026-09-30

Baker Bros. Advisors LP 15.09% · 30.76M sh
BlackRock 9.38% · 19.13M sh
Vanguard Capital Management, LLC 5.98% · 12.19M sh
Dodge & Cox 4.94% · 10.06M sh
State Street Global Advisors 4.84% · 9.86M sh
Vanguard Portfolio Management, LLC 3.81% · 7.77M sh
AQR Capital Management 2.66% · 5.43M sh
Geode Capital Management, LLC 2.40% · 4.89M sh
LSV Asset Management 1.90% · 3.88M sh
Wellington Management Group 1.65% · 3.36M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 33 buys · 17 sells

NameRoleStake
Baker Bros. Advisors LP -- 15.09%
Julian Baker Independent Chairperson 0.14%
Pablo Cagnoni President and Global Head of R&D 0.09%
Herve Hoppenot Former Advisor to CEO & Director 0.04%
Paula Swain Former Officer 0.03%
Christiana Stamoulis Former Chief Financial Officer 0.03%
Paul Clancy Independent Director 0.01%
Jean-Jacques Bienaime Independent Director 0.01%
Edmund Harrigan Independent Director 0.01%
David Gardner Chief Strategy Officer 0.01%
Katherine High Independent Director 0.01%
Jacqualyn Fouse Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-05 Steven Stein Executive VP, Head of Late-stage Development & Chief Medical Officer Derivative Exercise and Sale -240,193 $61.18–119.66
2026-11-02 Thomas Tray Principal Financial Officer, VP of Finance & Chief Accounting Officer Open Market Disposition -610 $118.96
2026-10-14 Pablo Cagnoni President and Global Head of R&D Derivative Exercise and Sale -2,642 $61.18–112.71
2026-09-30 Lee Heeson Executive VP & Head of Incyte International Sale to Issuer -463 $117.14
2026-09-29 Edmund Harrigan Independent Director Other Acquisition +206 $121.35
2026-09-29 Baker Bros. Advisors LP -- Other Acquisition +644 --
2026-09-29 Paul Clancy Independent Director Other Acquisition +203 $121.35
2026-09-21 David Gardner Chief Strategy Officer Sale to Issuer -920 $126.93
2026-09-14 Pablo Cagnoni President and Global Head of R&D Derivative Exercise and Sale -23,218 $61.18–120.50
2026-08-24 Soni Basi Executive Vice President Sale to Issuer -504 $129.72
2026-08-18 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -10,801 $125.56
2026-08-11 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -10,803 $120.04
2026-08-04 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -10,640 $122.69
2026-08-04 Patrick Mayes Vice President of Biotherapeutic Research Derivative Exercise and Sale -2,207 $106.47–123.99
2026-08-02 Patrick Mayes Vice President of Biotherapeutic Research Derivative Exercise and Sale -45,767 $61.18–122.19
2026-07-30 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -15,888 $119.70
2026-07-30 Patrick Mayes Vice President of Biotherapeutic Research Open Market Disposition -2,187 $119.41
2026-07-22 Michael Morrissey Executive VP & Head of Global Technical Operations Other Derivative Acquisition +6,426 $116.69
2026-07-22 Michael Morrissey Executive VP & Head of Global Technical Operations Other Derivative Acquisition +8,999 --
2026-07-22 Lee Heeson Executive VP & Head of Incyte International Other Derivative Acquisition +13,498 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:16 · For reference only, not investment advice and not tailored to your situation.

Incyte discussion 0 comments

Add a comment